Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach
Abstract
:1. Introduction
2. Methods
3. Results
3.1. Approved Systemic Therapies for Advanced BCC
3.1.1. Hedgehog Pathway Inhibitors
3.1.2. Vismodegib
3.1.3. Sonidegib
3.1.4. Immune-Checkpoint Inhibitors
3.2. Neoadjuvant Therapies Under Investigation for Advanced BCC
3.2.1. Hedgehog Pathway Inhibitors
3.2.2. Immune-Checkpoint Inhibitors
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lomas, A.; Leonardi-Bee, J.; Bath-Hextall, F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol. 2012, 166, 1069–1080. [Google Scholar] [CrossRef] [PubMed]
- Peris, K.; Fargnoli, M.C.; Kaufmann, R.; Arenberger, P.; Bastholt, L.; Seguin, N.B.; Bataille, V.; Brochez, L.; del Marmol, V.; Dummer, R.; et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur. J. Cancer 2023, 192, 113254. [Google Scholar] [CrossRef]
- Hoellwerth, M.; Brandlmaier, M.; Koelblinger, P. Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review. Cancers 2024, 17, 68. [Google Scholar] [CrossRef] [PubMed]
- Kiiski, V.; de Vries, E.; Flohil, S.C.; Bijl, M.J.; Hofman, A.; Stricker, B.H.C.; Nijsten, T. Risk factors for single and multiple basal cell carcinomas. Arch. Dermatol. 2010, 146, 848–855. [Google Scholar] [CrossRef]
- Queirolo, P.; Cinquini, M.; Argenziano, G.; Bassetto, F.; Bossi, P.; Boutros, A.; Clemente, C.; de Giorgi, V.; Del Vecchio, M.; Patuzzo, R.; et al. Guidelines for the diagnosis and treatment of basal cell carcinoma: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. ESMO Open 2023, 8, 102037. [Google Scholar] [CrossRef]
- Grob, J.J.; Gaudy-Marqueste, C.; Guminski, A.; Malvehy, J.; Basset-Seguin, N.; Bertrand, B.; Fernandez-Penas, P.; Kaufmann, R.; Zalaudek, I.; Fargnoli, M.; et al. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 2149–2153. [Google Scholar] [CrossRef]
- Sekulic, A.; Migden, M.R.; Oro, A.E.; Dirix, L.; Lewis, K.D.; Hainsworth, J.D.; Solomon, J.A.; Yoo, S.; Arron, S.T.; Friedlander, P.A.; et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 2012, 366, 2171–2179. [Google Scholar] [CrossRef]
- Migden, M.R.; Guminski, A.; Gutzmer, R.; Dirix, L.; Lewis, K.D.; Combemale, P.; Herd, R.M.; Kudchadkar, R.; Trefzer, U.; Gogov, S.; et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015, 16, 716–728. [Google Scholar] [CrossRef]
- Stratigos, A.J.; Sekulic, A.; Peris, K.; Bechter, O.; Prey, S.; Kaatz, M.; Lewis, K.D.; Basset-Seguin, N.; Chang, A.L.S.; Dalle, S.; et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021, 22, 848–857. [Google Scholar] [CrossRef]
- Long, G.V.; Menzies, A.M.; Scolyer, R.A. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. J. Clin. Oncol. 2023, 41, 3236–3248. [Google Scholar] [CrossRef]
- Zelin, E.; Zalaudek, I.; Agozzino, M.; Dianzani, C.; Dri, A.; Di Meo, N.; Giuffrida, R.; Marangi, G.F.; Neagu, N.; Persichetti, P.; et al. Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma. Curr. Treat. Options Oncol. 2021, 22, 35. [Google Scholar] [CrossRef] [PubMed]
- Dummer, R.; Ascierto, P.A.; Basset-Seguin, N.; Dréno, B.; Garbe, C.; Gutzmer, R.; Hauschild, A.; Krattinger, R.; Lear, J.; Malvehy, J.; et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: A joint expert opinion. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 1944–1956. [Google Scholar] [CrossRef]
- Carballo, G.B.; Honorato, J.R.; de Lopes, G.P.F.; Spohr, T.C.L.S.E. A highlight on Sonic hedgehog pathway. Cell Commun. Signal 2018, 16, 11. [Google Scholar] [CrossRef]
- Jing, J.; Wu, Z.; Wang, J.; Luo, G.; Lin, H.; Fan, Y.; Zhou, C. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct. Target. Ther. 2023, 8, 315. [Google Scholar] [CrossRef]
- Axelson, M.; Liu, K.; Jiang, X.; He, K.; Wang, J.; Zhao, H.; Kufrin, D.; Palmby, T.; Dong, Z.; Russell, A.M.; et al. US Food and Drug Administration approval: Vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin. Cancer Res. 2013, 19, 2289–2293. [Google Scholar] [CrossRef]
- Casey, D.; Demko, S.; Shord, S.; Zhao, H.; Chen, H.; He, K.; Putman, A.; Helms, W.S.; Keegan, P.; Pazdur, R. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. Clin. Cancer Res. 2017, 23, 2377–2381. [Google Scholar] [CrossRef] [PubMed]
- Sekulic, A.; Migden, M.R.; Basset-Seguin, N.; Garbe, C.; Gesierich, A.; Lao, C.D.; Miller, C.; Mortier, L.; Murrell, D.F.; Hamid, O.; et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017, 17, 332, Erratum in BMC Cancer 2019, 19, 366. [Google Scholar] [CrossRef]
- Basset-Seguin, N.; Hauschild, A.; Grob, J.J.; Kunstfeld, R.; Dréno, B.; Mortier, L.; Ascierto, P.A.; Licitra, L.; Dutriaux, C.; Thomas, L.; et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015, 16, 729–736. [Google Scholar] [CrossRef]
- Basset-Séguin, N.; Hauschild, A.; Kunstfeld, R.; Grob, J.; Dréno, B.; Mortier, L.; Ascierto, P.; Licitra, L.; Dutriaux, C.; Thomas, L.; et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur. J. Cancer 2017, 86, 334–348. [Google Scholar] [CrossRef]
- Dréno, B.; Kunstfeld, R.; Hauschild, A.; Fosko, S.; Zloty, D.; Labeille, B.; Grob, J.-J.; Puig, S.; Gilberg, F.; Bergström, D.; et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): A randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017, 18, 404–412. [Google Scholar] [CrossRef]
- Gutzmer, R.; Schulze, H.J.; Hauschild, A.; Leiter, U.; Meier, F.; Haferkamp, S.; Ulrich, C.; Wahl, R.U.; Berking, C.; Herbst, R.; et al. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany—The non-interventional study NIELS. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 1678–1685. [Google Scholar] [CrossRef] [PubMed]
- Verkouteren, B.J.A.; Wakkee, M.; Reyners, A.K.L.; Nelemans, P.; Aarts, M.J.B.; Rácz, E.; Terra, J.B.; Devriese, L.A.; Alers, R.-J.; Kapiteijn, E.; et al. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: A retrospective cohort study. Br. J. Cancer 2021, 124, 1199–1206. [Google Scholar] [CrossRef]
- Słowińska, M.; Dudzisz-Śledź, M.; Sobczuk, P.; Łasińska, I.; Pietruszka, A.; Cybulska-Stopa, B.; Kowalczyk, A.; Świtaj, T.; Czarnecka, I.; Koseła-Paterczyk, H.; et al. Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma—Real world multicenter cohort study. J. Eur. Acad. Dermatol. Venereol. 2022, 36, 1219–1228. [Google Scholar] [CrossRef]
- Dummer, R.; Guminksi, A.; Gutzmer, R.; Lear, J.T.; Lewis, K.D.; Chang, A.L.S.; Combemale, P.; Dirix, L.; Kaatz, M.; Kudchadkar, R.; et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br. J. Dermatol. 2020, 182, 1369–1378. [Google Scholar] [CrossRef]
- Herms, F.; Baroudjian, B.; Delyon, J.; Laly, P.; Tetu, P.; Lebbe, C.; Basset-Seguin, N. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study. Acta Derm. Venereol. 2022, 102, adv00740. [Google Scholar] [CrossRef] [PubMed]
- Mannino, M.; Piccerillo, A.; Fabbrocini, G.; Quaglino, P.; Argenziano, G.; Dika, E.; Ascierto, P.A.; Pellacani, G.; Longo, C.; Fargnoli, M.C.; et al. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness. Dermatology 2023, 239, 868–876. [Google Scholar] [CrossRef]
- Nikanjam, M.; Cohen, P.R.; Kato, S.; Sicklick, J.K.; Kurzrock, R. Advanced basal cell cancer: Concise review of molecular characteristics and novel targeted and immune therapeutics. Ann. Oncol. 2018, 29, 2192–2199, Erratum in Ann. Oncol. 2019, 30, 1675. [Google Scholar] [CrossRef]
- Stratigos, A.J.; Sekulic, A.; Peris, K.; Bechter, O.; Prey, S.; Lewis, K.D.; Basset-Seguin, N.; Chang, A.L.S.; Dalle, S.; Orland, A.F.; et al. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. J. Am. Acad. Dermatol. 2024, 90, 414–418. [Google Scholar] [CrossRef] [PubMed]
- Lewis, K.D.; Peris, K.; Sekulic, A.; Stratigos, A.; Dunn, L.; Eroglu, Z.; Chang, A.; Migden, M.; Yoo, S.-Y.; Mohan, K.; et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann. Oncol. 2024, 35, 221–228. [Google Scholar] [CrossRef]
- Nakayama, M.; Tabuchi, K.; Nakamura, Y.; Hara, A. Basal cell carcinoma of the head and neck. J. Skin Cancer 2011, 2011, 496910. [Google Scholar] [CrossRef]
- Wilde, D.C.; Glaun, M.E.; Wong, M.K.; Gross, N.D. Neoadjuvant Approaches to Non-Melanoma Skin Cancer. Cancers 2023, 15, 5494. [Google Scholar] [CrossRef]
- Bertrand, N.; Guerreschi, P.; Basset-Seguin, N.; Saiag, P.; Dupuy, A.; Dalac-Rat, S.; Dziwniel, V.; Depoortère, C.; Duhamel, A.; Mortier, L.; et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma. eClinicalMedicine 2021, 35, 100844. [Google Scholar] [CrossRef]
- Available online: https://clinicaltrials.gov/study/NCT03534947#study-plan (accessed on 7 April 2025).
- Available online: https://clinicaltrials.gov/study/NCT05929664#study-plan (accessed on 7 April 2025).
- McDermott, J.; Jimeno, A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today 2015, 51, 7–20. [Google Scholar] [CrossRef]
- Available online: https://www.clinicaltrials.gov/study/NCT04323202#study-plan (accessed on 7 April 2025).
- Rajan, A.; Kim, C.; Heery, C.R.; Guha, U.; Gulley, J.L. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum. Vaccin. Immunother. 2016, 12, 2219–2231. [Google Scholar] [CrossRef]
- Su, J.; Fu, Y.; Cui, Z.; Abidin, Z.; Yuan, J.; Zhang, X.; Li, R.; Zhao, C. Relatlimab: A novel drug targeting immune checkpoint LAG-3 in melanoma therapy. Front. Pharmacol. 2024, 14, 1349081. [Google Scholar] [CrossRef]
- Available online: https://clinicaltrials.gov/study/NCT06624475#study-plan (accessed on 7 April 2025).
- Heppt, M.V.; Gebhardt, C.; Hassel, J.C.; Alter, M.; Gutzmer, R.; Leiter, U.; Berking, C. Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives. Cancers 2022, 14, 4547. [Google Scholar] [CrossRef]
- Fordham, S.A.; Shao, E.X.; Banney, L.; Azer, M.; Dettrick, A. Management of basal cell carcinoma with pulmonary metastasis. BMJ Case Rep. 2023, 16, e251700. [Google Scholar] [CrossRef]
- Ahmed, M.; Muradashvili, T.; Soliman, S.; Ghaly, M. Metastatic insidious super giant basal cell carcinoma. BMJ Case Rep. 2022, 15, e249873. [Google Scholar] [CrossRef]
- Dumann, K.; Artz, N.; Ziemer, M. Complete Remission of Basal Cell Carcinoma Following Treatment with Cemiplimab After 2 Years. JAMA Dermatol. 2021, 157, 1004–1006. [Google Scholar] [CrossRef]
- Hollield, C.; Amara, S.; MLewin, J.; GLebwohl, M. Neoadjuvant Sonidegib for the Management of Locally Advanced Basal Cell Carcinoma: A Case Report. J. Drugs Dermatol. 2025, 24, 329–331. [Google Scholar] [CrossRef]
- Angnardo, L.; Humeda, Y.; Alexandraki, I.; Wolfe, C.M.; Cognetta, A.B., Jr. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma. J. Drugs Dermatol. 2021, 20, 552–554. [Google Scholar]
- Lehto, L.E.T.; Ristola, M.T.; Mäntylä, V.; Pajula, S. A Multidisciplinary approach to metastatic giant basal cell carcinoma-A case report. JPRAS Open 2024, 40, 190–193. [Google Scholar] [CrossRef]
- Peillex, D.; Passemard, L.; Magnin, B.; Rouanet, J.; Pham Dang, N. The Role of Surgery After Remission of Nonsystemic Extensive Periorbital Basal Cell Carcinoma Treated by Vismodegib: A Systematic Review. Dermatol. Surg. 2022, 48, 905–911. [Google Scholar] [CrossRef]
- Garbe, C.; Dummer, R.; Amaral, T.; Amaria, R.N.; Ascierto, P.A.; Burton, E.M.; Dreno, B.; Eggermont, A.M.M.; Hauschild, A.; Hoeller, C.; et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat. Med. 2023, 29, 1310–1312. [Google Scholar] [CrossRef]
- Topalian, S.L.; Pardoll, D.M. Neoadjuvant anti-PD-1-based immunotherapy: Evolving a new standard of care. J. Immunother. Cancer 2025, 13, e010833. [Google Scholar] [CrossRef]
- Paradisi, A.; Cornacchia, L.; Cappilli, S.; Abeni, D.; Federico, F.; Di Stefani, A.; Mannino, M.; Peris, K. Preoperative evaluation of high-risk basal cell carcinoma with line-field confocal optical coherence tomography (LC-OCT) reduces Mohs micrographic surgery stage number: A case-control study. EJC Ski. Skin. Cancer 2024, 2, 100015. [Google Scholar] [CrossRef]
- Cappilli, S.; Mannino, M.; Palmisano, G.; Bocchino, E.; Piccerillo, A.; Paradisi, A.; Di Stefani, A.; Peris, K. Locally advanced basal cell carcinoma treated with sonidegib: In vivo monitoring with line-field confocal optical coherence tomography. Ski. Skin. Health Dis. 2025, 5, 37–40. [Google Scholar] [CrossRef]
- Mtimet, L.; Boussingault, L.; Aktas, D.; Fontaine, M.; Cano, C.O.; Diet, G.; Lenoir, C.; Miyamoto, M.; Cinotti, E.; Tognetti, L.; et al. Line-field confocal optical coherence tomography of basal cell carcinoma: A retrospective study on diagnostic performance. J. Eur. Acad. Dermatol. Venereol. 2024, 35, 1099–1110. [Google Scholar] [CrossRef]
- Cantisani, C.; Musolff, N.; Longo, C.; Di Guardo, A.; Rovaldi, E.; Rossi, G.; Sasso, F.; Farnetani, F.; Rega, F.; Bánvölgyiv, A.; et al. Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment. J. Eur. Acad. Dermatol. Venereol. 2024, 38, 967–973. [Google Scholar] [CrossRef]
- Couzan, C.; Cinotti, E.; Labeille, B.; Vercherin, P.; Rubegni, P.; Cambazard, F.; Perrot, J. Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after vismodegib treatment. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 763–767. [Google Scholar] [CrossRef]
- Boostani, M.; Bozsányi, S.; Suppa, M.; Cantisani, C.; Lőrincz, K.; Bánvölgyi, A.; Holló, P.; Wikonkál, N.M.; Huss, W.J.; Brady, K.L.; et al. Novel imaging techniques for tumor margin detection in basal cell carcinoma: A systematic scoping review of FDA and EMA-approved imaging modalities. Int. J. Dermatol. 2025, 64, 287–301. [Google Scholar] [CrossRef] [PubMed]
- Tamas, T.; Dinu, C.; Lenghel, L.M.; Boțan, E.; Tamas, A.; Stoia, S.; Leucuta, D.C.; Bran, S.; Onisor, F.; Băciuț, G.; et al. High-Frequency Ultrasound in Diagnosis and Treatment of Non-Melanoma Skin Cancer in the Head and Neck Region. Diagnostics 2023, 13, 1002. [Google Scholar] [CrossRef] [PubMed]
- Corvino, A.; Catalano, F.; Cipolletta Campanile, A.; Cocco, G.; Pizzi, A.D.; Corvino, F.; Varelli, C.; Catalano, O. Interventional Ultrasound in Dermatology: A Pictorial Overview Focusing on Cutaneous Melanoma Patients. J. Ultrasound Med. 2022, 41, 3137–3144. [Google Scholar] [CrossRef]
NCT | Title of the Study | Phase | Intervention | Status |
---|---|---|---|---|
Hedgehog pathway inhibitors | ||||
NCT02667574 | Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC) (VISMONEO) | Phase II | Vismodegib Surgery | Completed |
NCT03534947 | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (SONIB) | Phase II | Sonidegib Imiquimod Surgery | Recruiting |
Immune-checkpoint inhibitors | ||||
NCT05929664 | Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery | Phase II | Cemiplimab Surgery | Recruiting |
NCT04323202 | Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of Head&Neck | Phase I | Pembrolizumab Surgery | Active, not recruiting |
NCT06624475 | Neoadjuvant Opdualag Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma | Phase II | Nivolumab Relatlimab Surgery | Not yet recruiting |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Paradisi, A.; Mannino, M.; Brunetti, F.; Bocchino, E.; Di Stefani, A.; Peris, K. Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach. J. Pers. Med. 2025, 15, 226. https://doi.org/10.3390/jpm15060226
Paradisi A, Mannino M, Brunetti F, Bocchino E, Di Stefani A, Peris K. Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach. Journal of Personalized Medicine. 2025; 15(6):226. https://doi.org/10.3390/jpm15060226
Chicago/Turabian StyleParadisi, Andrea, Maria Mannino, Francesco Brunetti, Enrico Bocchino, Alessandro Di Stefani, and Ketty Peris. 2025. "Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach" Journal of Personalized Medicine 15, no. 6: 226. https://doi.org/10.3390/jpm15060226
APA StyleParadisi, A., Mannino, M., Brunetti, F., Bocchino, E., Di Stefani, A., & Peris, K. (2025). Advanced Basal Cell Carcinoma: A Narrative Review on Current Systemic Treatments and the Neoadjuvant Approach. Journal of Personalized Medicine, 15(6), 226. https://doi.org/10.3390/jpm15060226